DEAR SHAREHOLDER,

Demonstrating progress is about embracing the steps along the journey and, like a carefully choreographed performance, requires planning, precision, coordination and fluidity. At Cytokinetics, every initiative contributes to a composition of synchronized motion, with each forward movement building on the last to propel us toward our goals. At Cytokinetics, we seek to align all elements of strategy and execution to ensure that every milestone brings us closer to realizing our Vision 2030, which foresees us becoming the leading muscle-focused specialty biopharmaceutical company intent on meaningfully improving the lives of patients through global access to our innovative medicines. In 2024, we made important progress, laying the foundation for executing on this ambitious vision.

Most notable among our achievements in 2024 were regulatory submissions for *aficamten* in the U.S., Europe and China. The filings were supported by positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of *aficamten* in obstructive HCM, which were presented earlier in the year and simultaneously published in the *New England Journal of Medicine.* Now, with the NDA accepted by FDA in the U.S., we are actively engaging FDA in advance of our PDUFA date of September 26, 2025, while also interacting with regulatory authorities in Europe and China to enable global access for *aficamten.* In preparation for potential approvals, throughout 2024, we accelerated commercial launch readiness activities, scaled infrastructure and strengthened our capabilities ahead of this expected key business transformation.

We also continued to advance the clinical development program for *aficamten.* We completed enrollment in MAPLE-HCM, the Phase 3 clinical trial evaluating *aficamten* as monotherapy compared to *metoprolol* as monotherapy in patients with obstructive HCM and expect to share top-line results in Q2 2025. We also progressed ACACIA-HCM, the pivotal Phase 3 clinical trial of *aficamten* in non-obstructive HCM, a rapidly growing segment of the HCM population, and started CEDAR-HCM, evaluating *aficamten* in pediatric patients with obstructive HCM. These clinical trials could enable potential label expansion and further product life cycle management.

With *aficamten* anchoring of our emerging specialty cardiology franchise, we also advanced two later-stage potential therapies. *Omecamtiv mecarbil,* a cardiac myosin activator, is the subject of COMET-HF, an ongoing confirmatory Phase 3 clinical trial in patients with heart failure with severely reduced ejection fraction. And CK-586, an additional cardiac myosin inhibitor, is the subject of AMBER-HFpEF, a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF). Both *omecamtiv mecarbil* and CK-586 target underserved patient populations at opposite ends of the spectrum of heart failure for which there are few available therapies, high unmet need and concentrated customer segments. Our specialty cardiology franchise is the cornerstone of our business, with the potential to deliver multiple medicines to patients over the next several years and as we hope will serve to return enduring growth for all of our shareholders.

At the same time, our mission to pioneer muscle biology innovation continues, with research focused to novel mechanisms. In 2024, we began a Phase 1 study of CK-089, a fast skeletal muscle troponin activator arising from our discovery and research, with potential therapeutic application to a specific type of muscular dystrophy.

In 2024, we also raised over $1 billion in cash through equity capital fundraising activities and a structured finance and royalty monetization deal with Royalty Pharma. This balanced and diversified fundraising provides a strong foundation to support the commercialization of *aficamten* while we also pursue R&D activities and take advantage of pipeline expansion opportunities consistent with strategic planning.

2025 is poised to be a pivotal year for Cytokinetics as we plan to go to market with our first medicine arising from our research. Guided by our Vision 2030, every step we take is purposeful, shaping the future we aspire to achieve. This year, we hope to catalyze our vision of transforming the lives of people with diseases of muscle dysfunction and to deliver on the promise of our science for patients while returning meaningfully growing and sustainable value to our shareholders.

Robert I. Blum
President and Chief Executive Officer

VISION2030

Empowering Muscle, Empowering Lives

To be the leading muscle-focused specialty biopharma company intent on meaningfully improving the lives of patients through global access to our innovative medicines

INNOVATION
Advance 2 approved products across 3 indications and 10 NMEs in our pipeline

IGNITION
Achieve broad access and rapid use of our medicines in >15 countries throughout North America and Europe

IMPACT
Reach >100,000 patients globally with our medicines

INSPIRATION
Foster a patient-centric culture with emphasis on equitable access

INGENUITY
Extend leadership in muscle biology deploying multiple therapeutic modalities